{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T21:39:05Z","timestamp":1784065145586,"version":"3.55.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100015438","name":"International Society on Thrombosis and Haemostasis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015438","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jtha.2025.02.012","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T12:08:22Z","timestamp":1739966902000},"page":"1717-1726","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Results of an international survey on the management of therapeutic intensity unfractionated heparin: communication from the SSCs of the ISTH"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3740-9005","authenticated-orcid":false,"given":"Isabelle","family":"Gouin-Thibault","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4338-3035","authenticated-orcid":false,"given":"Lana A.","family":"Castellucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6445-582X","authenticated-orcid":false,"given":"Jean M.","family":"Connors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6701-9417","authenticated-orcid":false,"given":"Michael","family":"Hardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8955-2407","authenticated-orcid":false,"given":"Alexandre","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6509-8964","authenticated-orcid":false,"given":"Virginie","family":"Siguret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6303-4732","authenticated-orcid":false,"given":"Corinne","family":"Frere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3766-4962","authenticated-orcid":false,"given":"Jerrold H.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3595-5697","authenticated-orcid":false,"given":"Adam","family":"Cuker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3269-6156","authenticated-orcid":false,"given":"Thomas","family":"Lecompte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6947-6099","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Mullier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2025.02.012_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-642-23056-1_1","article-title":"History of heparin","volume":"207","author":"Barrowcliffe","year":"2012","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.jtha.2025.02.012_bib2","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1111\/jth.13555","article-title":"A\u00a0century of heparin: past, present and future","volume":"14","author":"Hemker","year":"2016","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.012_bib3","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1111\/jth.14898","article-title":"Heparin - an old drug with multiple potential targets in COVID-19 therapy","volume":"18","author":"Lindahl","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.012_bib4","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1111\/jth.14933","article-title":"Clinical differentiation of anticoagulant and non-anticoagulant properties of heparin","volume":"18","author":"Thachil","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.012_bib5","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1055\/a-2359-0987","article-title":"Management of therapeutic-intensity unfractionated heparin: a narrative review on critical points","volume":"8","author":"Gouin-Thibault","year":"2024","journal-title":"TH Open"},{"key":"10.1016\/j.jtha.2025.02.012_bib6","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2146\/ajhp090123","article-title":"Weight-based heparin protocol using antifactor Xa monitoring","volume":"67","author":"Smith","year":"2010","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jtha.2025.02.012_bib7","doi-asserted-by":"crossref","first-page":"874","DOI":"10.7326\/0003-4819-119-9-199311010-00002","article-title":"The weight-based heparin dosing nomogram compared with a \u201cstandard care\u201d nomogram. A randomized controlled trial","volume":"119","author":"Raschke","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2025.02.012_bib8","doi-asserted-by":"crossref","DOI":"10.11613\/BM.2019.020503","volume":"29","author":"Broni\u0107","year":"2019","journal-title":"Biochem Med (Zagreb)"},{"key":"10.1016\/j.jtha.2025.02.012_bib9","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1515\/cclm-2024-0059","volume":"62","author":"Garcia-Castrillo","year":"2024","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.jtha.2025.02.012_bib10","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/ijlh.13584","article-title":"International Council for Standardisation in Haematology (ICSH) recommendations for collection of blood samples for coagulation testing","volume":"43","author":"Kitchen","year":"2021","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jtha.2025.02.012_bib11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.thromres.2019.10.019","article-title":"Monitoring unfractionated heparin therapy. 4 hour-stability of anti-Xa activity in unspun citrated tubes","volume":"186","author":"Toulon","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.02.012_bib12","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s11239-019-01882-1","article-title":"Is citrate theophylline adenosine dipyridamole (CTAD) better than citrate to survey unfractionated heparin treatment? Has delayed centrifugation a real impact on this survey?","volume":"48","author":"Billoir","year":"2019","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.jtha.2025.02.012_bib13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12959-023-00465-8","article-title":"Monitoring heparin therapy: stability of two different anti-Xa assays using blood samples collected in citrate-containing and CTAD tubes","volume":"21","author":"Gremillet","year":"2023","journal-title":"Thromb J"},{"key":"10.1016\/j.jtha.2025.02.012_bib14","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/0049-3848(83)90337-7","article-title":"Heparin inactivation during blood storage: its prevention by blood collection in citric acid, theophylline, adenosine, dipyridamole-C.T.A.D. mixture","volume":"31","author":"Contant","year":"1983","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.02.012_bib15","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1055\/s-0038-1651099","article-title":"Monitoring heparin therapy by the activated partial thromboplastin time--the effect of pre-analytical conditions","volume":"57","author":"van den Besselaar","year":"1987","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.012_bib16","first-page":"35","article-title":"Heparin neutralization by recombinant platelet factor 4 and protamine","volume":"81","author":"Levy","year":"1995","journal-title":"Anesth Analg"},{"key":"10.1016\/j.jtha.2025.02.012_bib17","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1515\/cclm-2020-0061","article-title":"The CRESS checklist for reporting stability studies: on behalf of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Working Group for the Preanalytical Phase (WG-PRE)","volume":"59","author":"Cornes","year":"2020","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.jtha.2025.02.012_bib18","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/MAT.0000000000002100","article-title":"Anti-Xa assay monitoring improves the precision of anticoagulation in venovenous extracorporeal membrane oxygenation","volume":"70","author":"Hla","year":"2024","journal-title":"ASAIO J"},{"issue":"Suppl","key":"10.1016\/j.jtha.2025.02.012_bib19","doi-asserted-by":"crossref","first-page":"e24S","DOI":"10.1378\/chest.11-2291","article-title":"Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Garcia","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.jtha.2025.02.012_bib20","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.thromres.2017.07.006","article-title":"Should we abandon the APTT for monitoring unfractionated heparin?","volume":"157","author":"Arachchillage","year":"2017","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.02.012_bib21","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1160\/TH06-05-0290","article-title":"Monitoring unfractionated heparin with the aPTT: time for a fresh look","volume":"96","author":"Eikelboom","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.012_bib22","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.thromres.2011.11.016","article-title":"Monitoring unfractionated heparin with APTT: a French collaborative study comparing sensitivity to heparin of 15 APTT reagents","volume":"129","author":"Gouin-Thibaut","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.02.012_bib23","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1055\/s-0032-1319770","article-title":"Unfractionated heparin for the treatment of venous thromboembolism: best practices and areas of uncertainty","volume":"38","author":"Cuker","year":"2012","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2025.02.012_bib24","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1515\/cclm-2020-0130","article-title":"Quality performance for indirect Xa inhibitor monitoring in patients using international external quality data","volume":"58","author":"Hollestelle","year":"2020","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.jtha.2025.02.012_bib25","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archinte.1994.00420010073009","article-title":"A\u00a0randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin","volume":"154","author":"Levine","year":"1994","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jtha.2025.02.012_bib26","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1080\/17474086.2017.1345306","article-title":"Therapeutic monitoring of unfractionated heparin - trials and tribulations","volume":"10","author":"Baluwala","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.jtha.2025.02.012_bib27","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/bjh.15013","article-title":"Inter-individual variability in phospholipid-dependent interference of C-reactive protein on activated partial thromboplastin time","volume":"183","author":"Erdem-Eraslan","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2025.02.012_bib28","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1515\/cclm-2014-0906","article-title":"Interference of C-reactive protein with clotting times","volume":"53","author":"Devreese","year":"2015","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.jtha.2025.02.012_bib29","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1177\/1076029617741363","article-title":"Performance of anti-factor Xa versus activated partial thromboplastin time for heparin monitoring using multiple nomograms","volume":"24","author":"Whitman-Purves","year":"2018","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.jtha.2025.02.012_bib30","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1592\/phco.19.9.760.31547","article-title":"Monitoring unfractionated heparin therapy with antifactor Xa activity results in fewer monitoring tests and dosage changes than monitoring with the activated partial thromboplastin time","volume":"19","author":"Rosborough","year":"1999","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jtha.2025.02.012_bib31","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/ijlh.14207","article-title":"Anti-factor Xa as the preferred assay to monitor heparin for the treatment of pulmonary embolism","volume":"46","author":"Zhu","year":"2024","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jtha.2025.02.012_bib32","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3389\/fmed.2019.00254","article-title":"Heparins: a shift of paradigm","volume":"6","author":"Hemker","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jtha.2025.02.012_bib33","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/j.1875-9114.2011.01049.x","article-title":"Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin","volume":"32","author":"Vandiver","year":"2012","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jtha.2025.02.012_bib34","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1345\/aph.1Q161","article-title":"Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by\u00a0continuous intravenous infusion","volume":"45","author":"Guervil","year":"2011","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jtha.2025.02.012_bib35","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1111\/jth.15264","article-title":"APTT therapeutic range for monitoring unfractionated heparin therapy. Significant impact of the anti-Xa reagent used for correlation","volume":"19","author":"Toulon","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.012_bib36","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1111\/jth.14969","article-title":"Monitoring unfractionated heparin therapy: lack of standardization of anti-Xa activity reagents","volume":"18","author":"Smahi","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.012_bib37","doi-asserted-by":"crossref","first-page":"700","DOI":"10.3390\/biomedicines9060700","article-title":"Optimization of heparin monitoring with anti-FXa assays and the impact of dextran sulfate for measuring all drug activity","volume":"9","author":"Amiral","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.jtha.2025.02.012_bib38","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1055\/s-0043-1770096","article-title":"Factors influencing anti-Xa assays: a multicenter prospective study in critically ill and noncritically ill patients receiving unfractionated heparin","volume":"123","author":"Lasne","year":"2023","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.012_bib39","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1055\/s-0038-1646008","article-title":"Modification of an amidolytic heparin assay to express protein-bound heparin and to correct for the effect of antithrombin III concentration","volume":"58","author":"Lyon","year":"1987","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.012_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.102257","article-title":"Reassessment of dextran sulfate in anti-Xa assay for unfractionated heparin laboratory monitoring","volume":"7","author":"Hardy","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.012_bib41","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.thromres.2003.09.014","article-title":"Dextran sulfate included in factor Xa assay reagent overestimates heparin activity in patients after heparin reversal by protamine","volume":"111","author":"Mouton","year":"2003","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.02.012_bib42","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1111\/bjh.19729","article-title":"Measurement of heparin, direct oral anti-coagulants and other non-coumarin anti-coagulants and their effects on haemostasis assays: a British Society for Haematology Guideline","volume":"205","author":"Baker","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2025.02.012_bib43","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1056\/NEJM197208172870703","article-title":"A\u00a0prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time","volume":"287","author":"Basu","year":"1972","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2025.02.012_bib44","doi-asserted-by":"crossref","first-page":"104","DOI":"10.7326\/0003-4819-119-2-199307150-00002","article-title":"Establishing a therapeutic range for heparin therapy","volume":"119","author":"Brill-Edwards","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2025.02.012_bib45","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jtha.2022.11.014","volume":"21","author":"Helms","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.012_bib46","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0002-9343(01)00715-X","article-title":"New heparin dosing recommendations for patients with acute coronary syndromes","volume":"110","author":"Menon","year":"2001","journal-title":"Am J Med"},{"key":"10.1016\/j.jtha.2025.02.012_bib47","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/FJC.0000000000001608","article-title":"Low-intensity heparin infusion compared with high-intensity heparin infusion dosing in patients with mechanical mitral valves: a retrospective cohort study","volume":"84","author":"Olsen","year":"2024","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.jtha.2025.02.012_bib48","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMra2104091","article-title":"Heparin resistance - clinical perspectives and management strategies","volume":"385","author":"Levy","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2025.02.012_bib49","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1016\/j.jtha.2023.08.013","article-title":"Defining heparin resistance: communication from the ISTH SSC Subcommittee of Perioperative and Critical Care Thrombosis and Hemostasis","volume":"21","author":"Levy","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.012_bib50","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-056912","article-title":"Improving safety of unfractionated heparin: a retrospective, quasi-experimental, observational study of the impact of a pocket card and a computerised prescription aid tool in the University Hospitals of Geneva","volume":"12","author":"Jimaja","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.jtha.2025.02.012_bib51","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1213\/ANE.0b013e31827e4e62","article-title":"Review article: heparin sensitivity and resistance: management during cardiopulmonary bypass","volume":"116","author":"Finley","year":"2013","journal-title":"Anesth Analg"},{"key":"10.1016\/j.jtha.2025.02.012_bib52","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/jth.14648","article-title":"Recommendations for clinical laboratory testing for antithrombin deficiency; communication from the SSC of the ISTH","volume":"18","author":"Van Cott","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.012_bib53","first-page":"85","article-title":"Anticoagulant effect of unfractionated heparin in antithrombin-depleted plasma in\u00a0vitro","volume":"26","author":"Krulder","year":"1996","journal-title":"Haemostasis"},{"key":"10.1016\/j.jtha.2025.02.012_bib54","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.thromres.2019.01.007","article-title":"Monitoring of heparins in antithrombin-deficient patients","volume":"175","author":"Croles","year":"2019","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.02.012_bib55","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1309\/8E3U7RXEPXNP27R7","article-title":"Comparative performance of three anti\u2013factor Xa heparin assays in patients in a medical intensive care unit receiving intravenous, unfractionated heparin","volume":"126","author":"Lehman","year":"2006","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jtha.2025.02.012_bib56","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1055\/s-0038-1646521","article-title":"The effect of trace amounts of tissue factor on thrombin generation in platelet rich plasma, its inhibition by heparin","volume":"61","author":"B\u00e9guin","year":"1989","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.012_bib57","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1055\/s-0038-1646990","article-title":"The mode of action of heparin in plasma","volume":"60","author":"B\u00e9guin","year":"1988","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.012_bib58","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1097\/CCM.0000000000004590","article-title":"A\u00a0randomized controlled trial of antithrombin supplementation during extracorporeal membrane oxygenation","volume":"48","author":"Panigada","year":"2020","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jtha.2025.02.012_bib59","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1097\/ALN.0000000000004920","article-title":"Antithrombin levels and heparin responsiveness during veno-arterial extracorporeal membrane oxygenation: a prospective single-center cohort study","volume":"140","author":"Mansour","year":"2024","journal-title":"Anesthesiology"},{"issue":"Suppl 1","key":"10.1016\/j.jtha.2025.02.012_bib60","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/ijlh.13230","article-title":"Thromboembolic events and apparent heparin resistance in patients infected with SARS-CoV-2","volume":"42","author":"Beun","year":"2020","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jtha.2025.02.012_bib61","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1055\/s-0039-1697950","article-title":"Surgical Clinical Outcome REsearch (SCORE) Group. Anti-factor Xa\u2013based anticoagulation during extracorporeal membrane oxygenation: potential problems and possible solutions","volume":"46","author":"Ranucci","year":"2020","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2025.02.012_bib62","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1213\/ANE.0000000000006145","article-title":"A\u00a0multicenter, randomized, double-blind, placebo-controlled trial of preoperative antithrombin supplementation in patients at risk for antithrombin deficiency after cardiac surgery","volume":"135","author":"Moront","year":"2022","journal-title":"Anesth Analg"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625001084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625001084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:37:37Z","timestamp":1777639057000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783625001084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":62,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1538783625001084"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2025.02.012","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Results of an international survey on the management of therapeutic intensity unfractionated heparin: communication from the SSCs of the ISTH","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2025.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}